Camurus is a Swedish science-led biopharmaceutical company committed to improving the lives of patients with severe and chronic diseases. We empower patients, support caregivers and create value for society by developing and giving access to innovative, long-acting medicines. To fulfill our commitment, we are determined to conduct our business in a sustainable manner.

New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® technology and extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of treatment of opioid dependence, cancer, and endocrine disorders, which are developed in-house and in collaboration with international pharmaceutical companies.

The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX.